Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yulei Zhuang"'
Autor:
Xianglei Gao, Yujing Di, Yuan Lv, Yingcai Luan, Yang Xiong, Yuli Xu, Yusheng Li, Linfeng Guo, Xiaoping Li, Li Deng, Yulei Zhuang, Jie Hou
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract This study aimed to evaluate the pharmacokinetics (PKs), safety, and immunogenicity of the biosimilar HEC14028 compared to reference Trulicity® (dulaglutide) in healthy male Chinese subjects. This study was a single‐center, randomized, op
Externí odkaz:
https://doaj.org/article/ed5a962c056a4f96a6e28ac95d130d16
Autor:
Ruirui Zhou, Linfeng Guo, Xianglei Gao, Yijun Wang, Wenjing Xu, Yang Zou, Wenjia Li, Yulei Zhuang, Gangyi Liu, Yanmei Liu
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 10, Pp 2458-2467 (2022)
Abstract This study aimed to evaluate the pharmacokinetics (PKs), safety, and immunogenicity of the biosimilar (RD12014) compared to reference liraglutide (Victoza) in healthy Chinese male subjects, so as to provide the basis for the similarity evalu
Externí odkaz:
https://doaj.org/article/ca5a6593c1e84b88bb977b782ce8dc66
Pharmacokinetics, pharmacodynamics, and safety of prandial oral insulin (N11005) in healthy subjects
Autor:
Qi Pan, Xiaoxia Wang, Wenjia Li, Xiaofeng Chen, Yulei Zhuang, Qinghong Zhou, Yuhui Huang, Yijie Zhou, Li Lan, Zhijie Wang, Wenjia Wang, Juan Hong, Wei-Hua Hao, Yu-Tsai Yang, Lixin Guo
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
AimsTo verify whether the oral insulin N11005 is administered as a prandial insulin by assessing the pharmacokinetics (PK), pharmacodynamics (PD), and safety profiles of N11005 with a short-acting biosynthetic human insulin (Novolin R) as reference.M
Externí odkaz:
https://doaj.org/article/2b7a751b45a44181baee12e90d3a9c23
Autor:
Rongrui Liu, Lianke Liu, Chuanhua Zhao, Yuxian Bai, Yulong Zheng, Shu Zhang, Ning Li, Jianwei Yang, Qingxia Fan, Xiuwen Wang, Shan Zeng, Yingjun Zhang, Weihong Zhang, Yulei Zhuang, Ning Kang, Yingzhi Jiang, Hongmei Sun, Jianming Xu
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squ
Externí odkaz:
https://doaj.org/article/c296492a15704d349fdc15b8b90df437
Autor:
Yingzhi Jiang, Ning Li, Ning Kang, Qingxia Fan, Xiuwen Wang, Yulong Zheng, Rongrui Liu, Shu Zhang, Jianwei Yang, Weihong Zhang, Lianke Liu, Yingjun Zhang, Jianming Xu, Hongmei Sun, Chuanhua Zhao, Yuxian Bai, Yulei Zhuang, Shan Zeng
Publikováno v:
BMC Gastroenterology
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-11 (2021)
Background Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db087510dac3706507186f06921cb717
https://doi.org/10.21203/rs.3.rs-517047/v2
https://doi.org/10.21203/rs.3.rs-517047/v2
Publikováno v:
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 34(12)
To study the chemical constituents of the whole plant of fresh celery (Apium graveolens).The constituents were isolated and purified by silica gel, Sephadex LH-20, ODS column chromatography, PTLC, HPLC, and their structures were elucidated on the bas